Table 2 Inhibition values of ACE2 construct against pseudotyped SARS-CoV-2 variants and SARS-CoV-1

From: Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist

Pseudotyped SARS-CoV-2 inhibition

Variant

IC50 (nM)

 

ACE2 monomer

T0A

T1A

T3A

T5A

T18A

TD3ADR273Q

TD3ADH345F

Wuhan-Hu-1

22 ± 5.5

0.6 ± 0.2

0.2 ± 0.1

0.7 ± 0.1

0.4 ± 0.1

0.1 ± 0.2

-

-

Delta B.1.617.2

24 ± 5.8

0.8 ± 0.4

0.4 ± 0.2

0.5 ± 0.2

0.2 ± 0.1

0.4 ± 0.1

-

-

Omicron BA.1

16 ± 4.0

0.2 ± 0.1

0.1 ± 0.02

0.2 ± 0.04

0.1 ± 0.02

0.03 ± 0.01

-

-

Arcturus XBB.1.16

-

-

-

0.4 ± 0.1

-

-

0.6 ± 0.2

0.4 ± 0.7

Pseudotyped SARS-CoV inhibition

 

IC50 (nM)

 

ACE2 monomer

T0A

T1A

T3A

T5A

T18A

TD3ADR273Q

TD3ADH345F

SARS-CoV-1 (28aa del)

3300 ± 900

-

-

0.6 ± 0.2

-

-

1.5 ± 0.4

2.2 ± 0.5